Median OS was 16 months for nivolumab versus 14 months for ICC; this data should however be interpreted with caution as patients enrolled in the ICC group could thereafter be treated by anti-PD1 or anti-BRAF targeted therapies. This evidence concerns the gene BRAF and intrahepatic cholangiocarcinoma.